
Sunday, July 16, 2017 2:36:27 PM
Award-winning platform, outstanding pre-clinical with proven MOAs and targets, strong team, multi-billion dollar markets for both lead compounds consisting of several potential indications.
Will have 3-4 candidates in clinic by end of 2018, 2 internal and 1-2 with partners (Merck KgaA and/or Takeda). Recent IPO (June) with steady flow of milestones (up to $2B) from partnerships.
Looking at a 5-year 10-bagger here...good luck to all.
Will post often here.

Liked By
Spread the love. Be the first to like this post!
Recent MRSN News
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/03/2023 09:05:00 PM
- Mersana Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/02/2023 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/01/2023 01:19:18 PM
- Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer • GlobeNewswire Inc. • 02/01/2023 01:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/31/2023 07:02:46 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/25/2023 01:25:17 PM
- Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors • GlobeNewswire Inc. • 01/25/2023 01:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/19/2023 09:07:23 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/06/2023 09:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/06/2023 12:19:46 PM
- Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones • GlobeNewswire Inc. • 01/06/2023 12:00:18 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/27/2022 12:03:21 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/22/2022 09:23:22 PM
- Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates • GlobeNewswire Inc. • 12/22/2022 09:05:10 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/16/2022 09:47:13 PM
- European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer • GlobeNewswire Inc. • 12/14/2022 01:00:00 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/02/2022 09:05:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/02/2022 09:03:03 PM
- SVB Securities Sticks to Their Buy Rating for Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:27:37 AM
- Robert W. Baird Remains a Buy on Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:16:29 AM
- Mersana Therapeutics to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2022 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 09:06:49 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 11/07/2022 09:03:59 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/07/2022 01:49:36 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 12:11:32 PM
Xalles Announces 2022 Results and Organizational Changes • XALL • Feb 6, 2023 8:39 AM
TNRG Signs Reg A Offering Agreement • TNRG • Feb 3, 2023 10:30 AM
Trend Innovations Holding Inc. Thy News Application Review Year 2022 and Update Toward 2023 • TREN • Feb 2, 2023 2:00 PM
Goldshore Intersects 9.46 g/t Au over 7.45m in the Southwest Zone Widths of Mineralized System Expanded Significantly. • GSHRF • Feb 2, 2023 9:58 AM
Hempacco and Snoop Dogg Create Joint Venture to Launch Consumer Goods Powerhouse of Hemp and Hemp-Derived Products • HPCO • Feb 2, 2023 9:30 AM
Kona Gold Beverage, Inc Announces Record Revenue Month in January Eclipsing Half a Million Dollars for the First Time • KGKG • Feb 2, 2023 9:00 AM